Chronic respiratory disease, asthma, COPD, cystic fibrosis, and pulmonary fibrosis, remains one of the largest and most persistent burdens in medicine, driven by smoking, air pollution, occupational exposure, and genetics. For decades the field relied on a small toolkit of inhaled bronchodilators and corticosteroids. That is changing. Biologics that target specific inflammatory pathways are reshaping severe asthma, CFTR modulator therapy has become one of the clearest proof points for genotype-guided precision medicine in modern drug development, and digital tools, home spirometry, smart inhalers, remote monitoring, are finally giving pulmonologists the continuous data that cardiology and diabetes care have had for years. For pre-seed investors, the opportunity sits at the intersection of validated biology (Type 2 inflammation, CFTR trafficking, fibrotic signaling) and the tooling needed to phenotype patients precisely enough to give a therapy its best shot. Sonnerie evaluates respiratory spinouts the way it evaluates every opportunity: strong founding science from a university lab, an operator who can translate it, and a capital-efficient path to a first meaningful human data point.
What is the burden of chronic respiratory disease, and why does it matter to investors?
Chronic respiratory conditions, principally asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and pulmonary fibrosis, sit among the most common and most costly categories of chronic illness across both developed and developing health systems. Public-health data has long shown that chronic respiratory disease ranks among the leading categories of noncommunicable disease burden worldwide, generally behind cardiovascular disease and cancer but still accounting for a substantial share of global disability, with the exact ranking shifting by region and by how conditions are coded. Asthma affects a meaningful share of both children and adults in every country where it has been studied, COPD is heavily concentrated in current and former smokers and in populations with high biomass fuel or occupational dust exposure, and pulmonary fibrosis, while comparatively rare, carries a prognosis that clinicians have long compared unfavorably to many cancers in its most severe form.
The risk-factor landscape is instructive for where innovation can land. Tobacco smoke remains the dominant driver of COPD and a major aggravator of asthma. Ambient air pollution, particulate matter from traffic and industry, is an increasingly well-documented contributor to both disease onset and exacerbation. Occupational exposures, dusts, fumes, certain chemical classes, drive a meaningful subset of adult-onset asthma and fibrotic lung disease. Cystic fibrosis is different in kind: it is a single-gene, autosomal recessive disorder caused by mutations in the CFTR gene, which makes it a genetics story rather than an exposure story, and, as discussed below, one of the clearest templates for precision medicine in the lung.
For a venture investor, this burden profile matters for two reasons. First, the patient populations are large enough that even a narrowly defined biomarker-selected subgroup can support a viable commercial indication. Second, unmet need is unevenly distributed: primary care asthma and mild COPD are comparatively well served by generic inhaled therapy, while severe, treatment-refractory, and fibrotic disease remain underserved, which is exactly where high-risk, high-reward science tends to concentrate.
Why are biologics replacing inhalers as the frontier of asthma and COPD treatment?
For most of the modern history of asthma and COPD care, treatment has meant two mechanisms delivered locally to the airway: bronchodilators, which relax airway smooth muscle, and inhaled corticosteroids, which dampen airway inflammation broadly. These remain the backbone of guideline-based care and will likely remain first-line for the majority of patients for the foreseeable future, because they are inexpensive, largely generic, and effective for most people most of the time.
The frontier has moved to the subset of patients whose disease does not respond adequately to that backbone, so-called severe or refractory asthma, and to the biological subtypes underlying it. Research over the past two decades has clarified that a large share of severe asthma is driven by Type 2 inflammation, a signaling program built around cytokines including IL-4, IL-5, and IL-13, along with upstream alarmins such as TSLP and IL-33 released by airway epithelium in response to irritants and allergens. Biologic therapies that block specific nodes in this pathway, monoclonal antibodies aimed at IgE, IL-5 signaling, the IL-4/IL-13 receptor complex, and TSLP, have improved outcomes for appropriately selected patients, reducing exacerbations and steroid dependence in ways that were not achievable with inhaled therapy alone.
The strategic lesson for investors is that respiratory disease is no longer treated as a single entity but as a collection of inflammatory endotypes that must be identified before the right drug can be chosen. That creates a durable role for diagnostics and biomarker tools, blood eosinophil counts, exhaled nitric oxide, allergen-specific IgE, alongside the therapeutics themselves, and it opens space for non-Type 2 or mixed-inflammation asthma and COPD, phenotypes for which no biologic yet exists and which represent a genuine white space for new biology originating in academic labs.
What does cystic fibrosis teach venture investors about precision medicine in respiratory disease?
Cystic fibrosis is caused by mutations in a single gene, CFTR, which encodes a chloride channel in epithelial cell membranes. Loss of CFTR function thickens mucus in the lungs, pancreas, and other organs, driving chronic infection, progressive lung damage, and, historically, a markedly shortened life expectancy. For decades, CF care was almost entirely supportive: airway clearance, inhaled antibiotics, and management of downstream complications, because there was no way to correct the underlying protein defect.
That changed with the development of CFTR modulators, small molecules that either help the misfolded CFTR protein reach the cell surface (correctors) or help it open more effectively once there (potentiators). Combination modulator regimens, developed and refined over roughly a decade and a half, now provide substantial clinical benefit to the large majority of the CF population, those carrying the most common CFTR mutations. This is one of the clearest cases in modern drug development of a therapy engineered directly against a validated molecular defect, matched to patients by genotype, delivering benefit that supportive care alone could not achieve.
The lesson for respiratory investing generally is threefold. First, when a disease has a well-defined molecular lesion, precision, small-molecule or biologic therapy matched to genotype or endotype, tends to outperform broad anti-inflammatory approaches. Second, the CF story also shows the limits of the model: patients with rare or nonsense CFTR mutations, and those in regions without access to modulator therapy, remain underserved, which is a reminder that precision medicine’s benefits are not automatically distributed evenly and that next-generation approaches, including gene and RNA-based strategies, still have real room to run. Third, CF demonstrates the value of registries and natural-history data built by academic and patient-foundation consortia, infrastructure that substantially de-risks clinical development and is a pattern worth looking for in other respiratory spinouts.
Where does pulmonary fibrosis fit in the respiratory investment thesis?
Idiopathic pulmonary fibrosis (IPF) and related fibrotic interstitial lung diseases represent a smaller patient population than asthma or COPD but a disproportionately severe one. Progressive scarring of lung tissue impairs gas exchange over months to years, and for a long time the field had no disease-modifying therapy at all. Antifibrotic agents approved in the mid-2010s slow the rate of lung-function decline for many patients but do not reverse fibrosis or halt it entirely, leaving substantial unmet need for therapies that act on fibrotic signaling pathways, including those implicated in wound-healing gone awry, or that can be combined with anti-inflammatory or antifibrotic mechanisms.
Diagnosis itself is a bottleneck. IPF is frequently diagnosed late, after meaningful lung function has already been lost, in part because early symptoms overlap with common conditions and because confirmatory high-resolution imaging and specialist referral pathways are inconsistent. This makes earlier, more accurate diagnostics, whether imaging-based, blood-biomarker-based, or algorithmic, a genuine adjacent opportunity to therapeutics in this space, and one well suited to academic pulmonology and radiology labs that sit on relevant patient cohorts and imaging datasets.
How is the device and digital side of respiratory care evolving?
Respiratory medicine has historically lagged cardiology and diabetes in continuous, real-world monitoring, largely because lung function has been measured episodically, in a clinic, using spirometry that requires training and cooperation to perform well. That is shifting. Connected inhalers that log time and technique of use address the long-standing problem of poor adherence and poor inhaler technique, both of which are major, underappreciated drivers of avoidable exacerbations and hospitalizations. Home spirometry and simplified peak-flow devices, paired with smartphone apps, allow patients and clinicians to see trends between visits rather than relying on a single snapshot. Remote monitoring platforms that combine symptom diaries, pulse oximetry, and device-use data are beginning to enable earlier intervention before an exacerbation becomes severe enough to require emergency care.
For investors, this device and digital layer matters for two reasons beyond direct commercial potential. It generates the real-world data that pairs naturally with biologic and precision-medicine strategies, since knowing which patients are actually adherent and which are truly refractory is what makes a biomarker-selected trial or a stratified commercial launch credible. And it tends to be capital-efficient relative to novel biologics, which makes device- and software-enabled respiratory ventures a natural early or companion investment even within a thesis centered on therapeutics.
What does a fundable pre-seed respiratory spinout look like?
Across the sub-areas above, asthma and COPD biologics, CFTR-adjacent and other genetic-medicine approaches, fibrosis biology, and respiratory devices and diagnostics, the pattern of what makes a pre-seed respiratory company fundable is consistent.
- A defined biological or mechanical hypothesis, ideally a specific inflammatory node, genetic lesion, fibrotic pathway, or measurement problem, rather than a broad platform claim without a lead application
- Founding intellectual property that originated in a university lab, with data, even early and unpolished, generated by the founding scientist rather than assembled after the fact
- A credible plan to identify the right patient subgroup, since respiratory disease increasingly requires endotyping, biomarker, or genotype strategies to show a treatment effect at all
- A founding team that pairs the originating scientist with an operator capable of running a company, since academic labs rarely have in-house the regulatory, clinical, or commercial experience a therapeutics or device company needs
- A capital-efficient path to a first meaningful signal, whether that is a defined preclinical milestone, a small proof-of-mechanism study, or a device validation study, achievable without requiring a large up-front raise
- Awareness of the existing standard of care and a clear articulation of why current inhaled therapy, biologics, or antifibrotics leave a specific population underserved
How does Sonnerie evaluate respiratory opportunities?
Sonnerie is a pre-seed and seed venture firm focused on healthcare and life sciences, built around backing university spinouts and operator-led teams as a first institutional check. In respiratory disease, that translates into a specific posture: we look for founding science that engages directly with the mechanisms above, a novel node in Type 2 or non-Type 2 inflammation, a genetic or RNA-based approach relevant to CFTR or another respiratory gene target, a differentiated fibrotic pathway, or a device or monitoring approach that solves a real phenotyping or adherence problem, and that has come out of a lab with genuine depth in pulmonary biology, immunology, or genetics.
We spend as much time evaluating the team as the science. Respiratory therapeutics and devices both face real regulatory and reimbursement complexity, and the strongest spinouts we see pair a scientific founder with an operator who has already worked through some version of that path, whether in a prior biotech, a device company, or a digital health venture. As with every therapeutic area we cover, our role as a first institutional check is to help translate a strong academic result into a company with a clear, near-term plan for its next value-creating milestone, not to underwrite a finished commercial thesis. This is educational commentary on the field, not investment advice, and it does not describe the terms, size, or performance of any Sonnerie fund.
Frequently asked questions
Why is respiratory disease considered an attractive area for early-stage biotech investment?
Because it combines very large, well-characterized patient populations with a genuine scientific inflection point: the shift from broad inhaled anti-inflammatory therapy toward biologics and precision approaches matched to specific inflammatory or genetic subtypes. That shift creates room for new biology, new biomarkers, and new devices, particularly in severe asthma, COPD, and pulmonary fibrosis, where current standard of care leaves meaningful unmet need.
What is the difference between a bronchodilator and a biologic in asthma treatment?
Bronchodilators relax airway smooth muscle to relieve airflow obstruction and act quickly but do not address underlying inflammation. Inhaled corticosteroids reduce airway inflammation broadly. Biologics are monoclonal antibodies that block specific inflammatory signals, such as IL-5 or the IL-4/IL-13 receptor, and are reserved for patients with severe, biomarker-defined disease that does not respond adequately to inhaled therapy alone.
What are CFTR modulators and why are they significant?
CFTR modulators are small-molecule drugs that correct or potentiate the function of the CFTR chloride channel, the protein defective in cystic fibrosis. Combination modulator regimens deliver substantial clinical benefit to most patients carrying common CFTR mutations, making CF one of the clearest real-world examples of genotype-matched precision medicine, though patients with rarer mutations remain underserved.
How does home spirometry and remote monitoring change respiratory care?
Traditional spirometry is performed episodically in a clinic. Home spirometry and connected inhalers allow continuous or frequent measurement of lung function and medication adherence between visits, helping clinicians catch deterioration earlier and helping researchers stratify patients more precisely for biomarker-driven therapies.
What does Sonnerie look for in a pre-seed respiratory spinout?
A defined biological or mechanical hypothesis originating from university-generated data, a credible strategy for identifying the right patient subgroup, a founding team that pairs the originating scientist with an operator, and a capital-efficient plan to reach a first meaningful proof point, rather than a broad platform claim without a lead application.
Is smoking still the main risk factor for chronic respiratory disease?
Tobacco smoke remains the dominant driver of COPD and a significant aggravator of asthma, but it is not the only risk factor. Ambient air pollution, occupational exposure to dusts and fumes, and, for cystic fibrosis, inherited CFTR mutations, are all well-established contributors that shape where innovation is needed.